Treatment Armamentarium for HER2+ Metastatic Breast Cancer

Video

Comprehensive insight to the treatment armamentarium for HER2+ metastatic breast cancer throughout several lines of therapy.

Recent Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
Related Content
28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

Gabrielle Rocque;Joanne L. Blum, MD, PhD;Yan Ji;Eric Gauthier;Yao Wang;Monica Z. Montelongo;Joseph C. Cappelleri;Connie Chen;Meghan S. Karuturi;Debu Tripathy, MD
July 24th 2024
Article
Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Erika P. Hamilton, MD;Sara A. Hurvitz, MD;Sara M. Tolaney, MD, MPH;Virginia Kaklamani, MD, DSc;Paula Muñoz Romero;Shannon Matheny;Kathy Puyana Theall;Joyce A. O’Shaughnessy
July 21st 2024
Article
Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Finding a Place for Exercise Oncology in the Treatment of Breast Cancer

Neil M. Iyengar, MD
May 20th 2024
Podcast

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Two dose-limiting toxicities were observed, and the maximum tolerated dose was not reached in a study evaluating FS-1502 safety, tolerability, and efficacy.

FS-1502 Demonstrates Promising Antitumor Activity in HER2+ Breast Cancer

Roman Fabbricatore
July 19th 2024
Article

Two dose-limiting toxicities were observed, and the maximum tolerated dose was not reached in a study evaluating FS-1502 safety, tolerability, and efficacy.

31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

Hope S. Rugo, MD;Nadia Harbeck, MD, PhD;Priya Rastogi, MD;Joyce O’Shaughnessy, MD;Frances Boyle;Javier Cortés, MD;Matthew P. Goetz, MD;Erika P. Hamilton, MD;Chiun-Sheng Huang;Elżbieta Senkus;Alexey Tryakin;Patrick Neven, MD, PhD;Jens Huober, MD;Ran Wei;Valérie André;Maria Munoz;Belen San Antonio;Ashwin Shahir;Miguel Martin, MD, PhD;Stephen Johnston
July 9th 2024
Article